CAR T-Cell эмчилгээ Энэтхэг оны өртөг

CAR T-Cell эмчилгээ гэж юу вэ?

CAR T-эсийн эмчилгээ нь хорт хавдартай тэмцэхийн тулд таны биеийн дархлааны системийг ашигладаг хорт хавдрын дэвшилтэт эмчилгээний нэг төрөл юм. гэсэн утгатайХимерик антиген рецепторын Т эсийн эмчилгээ. Энэ үйл явцад эмч нар өвчтөний Т-эсийг (халдвараас хамгаалахад тусалдаг цагаан эсийн нэг төрөл) цуглуулж, хорт хавдрын эсийг таньж, устгахын тулд дахин програмчилдаг.

Т-эсүүд нь лабораторид тусгай рецепторуудыг (CARs) гадаргуу дээр нь зөөвөрлөхийн тулд өөрчилдөг. Эдгээр рецепторууд нь Т-эсийг хорт хавдрын эсүүдэд байдаг тодорхой уурагтай холбох боломжийг олгодог. Эдгээр "хэт цэнэглэгдсэн" эсүүд өвчтөний биед буцаж орсны дараа тэд хорт хавдрын эсийг идэвхтэй хайж, устгадаг.

Энэ эмчилгээ нь эрүүл эд эсийг хамгаалж, хорт хавдрыг довтолдог гэсэн үг юм. Энэ нь зарим төрлийн цусны хорт хавдрыг эмчлэхэд чухал ач холбогдолтой юмВ эсийн лимфома, цочмог лимфобластик лейкеми (БҮХ),болонолон миелома, ялангуяа хими эмчилгээ, цацраг туяа зэрэг бусад эмчилгээ амжилтгүй болсон үед.

CAR T-эсийн эмчилгээ нь онкологи дахь тоглоомыг өөрчилдөг бөгөөд эмчилгээний боломж хязгаарлагдмал хорт хавдартай өвчтөнүүдэд итгэл найдвар төрүүлдэг. Уг эмчилгээ нь хорт хавдрын стандарт эмчилгээнээс ялгаатай бөгөөд урьд нь эдгэрэх боломж хомс байсан олон өвчтөнд урт хугацааны эдгэрэлт өгдөг.

CAR T-Cell эмчилгээ хэнд хэрэгтэй вэ?

CAR T-эсийн эмчилгээг тодорхой төрлийн цусны хорт хавдартай хүмүүст, ялангуяа хими эмчилгээ, цацраг туяа, үүдэл эс шилжүүлэн суулгах гэх мэт уламжлалт эмчилгээ үр дүнд хүрээгүй тохиолдолд хэрэглэдэг. Энэ нь эхний ээлжийн эмчилгээ биш боловч дахилттай эсвэл галд тэсвэртэй хорт хавдартай өвчтөнүүдэд хүчтэй сонголт бөгөөд өвчин нь эргэж ирсэн эсвэл өмнөх эмчилгээнд хариу өгөхгүй гэсэн үг юм.

Энэ эмчилгээг хамгийн их хэрэглэдэг:

• В эсийн цочмог лимфобластын лейкеми (БҮХ): Ялангуяа стандарт эмчилгээнд хариу өгөөгүй хүүхэд, залуучуудад.
• Сарнисан том В эсийн лимфома (DLBCL)Ходжкины бус лимфома болон бусад төрлийн: Системийн эмчилгээний дор хаяж хоёр шугам амжилтгүй болсон өвчтөнүүдэд.
• Олон миелома: Ялангуяа протеазом дарангуйлагч эсвэл моноклональ эсрэгбие зэрэг бусад эмчилгээ үр дүнгүй болсон үед.

CAR T-эсийн эмчилгээнд хамрагдахын тулд хорт хавдартай өвчтөнүүд тодорхой нөхцлийг хангасан байх ёстой.

• Хорт хавдар нь CAR-ийн Т эсүүд чиглэж чадах тодорхой маркеруудыг (CD19 эсвэл BCMA гэх мэт) илэрхийлэх ёстой.
• Өвчтөн эмчилгээний үйл явц, түүний дотор аливаа гаж нөлөөг даван туулахад хангалттай эрүүл байх ёстой.
• Өвчтөн хяналтгүй халдвар, хүнд эрхтэний дутагдалтай байх ёсгүй.
• Ихэнх тохиолдолд CAR T-эсийн эмчилгээг авч үзэхийн өмнө бусад эмчилгээний аргуудын өмнөх бүтэлгүйтэл шаардлагатай байдаг.

Эмч нар зөвшөөрөл авахаасаа өмнө цусны шинжилгээ, дүрсний судалгаа, эрхтэний үйл ажиллагааны үнэлгээ зэрэг янз бүрийн шинжилгээ хийдэг. Мөн хамрагдах эсэх нь батлагдсан CAR T-эсийн бүтээгдэхүүн, эмчилгээ хийлгэж буй улсад тухайн хорт хавдрын тодорхой төрлийн зохицуулалтын зөвшөөрөл зэргээс хамаарна.

CAR T эсийн эмчилгээний журам

CAR T эсийн эмчилгээ нь нарийн төлөвлөсөн, алхам алхмаар үйл явц юм. Энэ нь таны дархлааны эсүүдийг цуглуулж, хорт хавдрыг таньж мэдэхийн тулд лабораторид өөрчлөх, дараа нь өвчинтэй тэмцэхийн тулд биедээ буцааж оруулах явдал юм. Энэ нь эхнээс нь дуустал хэрхэн ажилладаг вэ:

1. Лейкаферез (Т-эсийн цуглуулга):Уг процесс нь лейкаферез гэж нэрлэгддэг процедураас эхэлдэг. Өвчтөнөөс цусыг судсаар авдаг бөгөөд машин нь Т эсийг (цагаан эсийн нэг төрөл) ялгадаг. Цусны үлдсэн хэсэг нь биед буцаж ирдэг. Уг процедур нь хэдэн цаг үргэлжилдэг бөгөөд амбулаторийн аргаар хийгддэг.
2. Лабораторид эсийн инженерчлэл:Цуглуулсан Т эсийг генетикийн хувьд өөрчилсөн лабораторид илгээдэг. Лабораторийн мэргэжилтнүүд Т эсүүдэд шинэ генийг оруулж, тэдгээрийг Chimeric Antigen Receptor (CAR) хэмээх тусгай рецептороор тоноглодог. Энэхүү CAR нь эсүүдэд хорт хавдрын эсүүд дээрх тодорхой уурагуудыг таньж, холбоход тусалдаг.
3. Эсийн үржүүлэх:Т-эсийг зохион бүтээсний дараа лабораторид олноор нь ургуулдаг. Энэ нь 2-оос 3 долоо хоног шаардагдана. Зорилго нь хорт хавдрын эсийг онилж устгах чадвартай сая сая хүчирхэг CAR T эсийг бий болгох явдал юм.
4. Нөхцөл байдлын эмчилгээ (суслахын өмнөх хими эмчилгээ):CAR Т эсийг дусаахаас өмнө өвчтөнүүд ихэвчлэн 3-5 хоног үргэлжилдэг богино хугацааны хими эмчилгээ хийдэг. Энэ нь дархлааны системийг бага зэрэг сулруулахад тусалдаг бөгөөд шинэ CAR Т эсүүд бие махбодид орсны дараа илүү үр дүнтэйгээр өргөжиж, ажиллах боломжийг олгодог.
5. CAR T-Cell Infusion:Лабораторид бэлтгэсэн эсүүд бэлэн болсны дараа тэдгээрийг судсаар дамжуулан өвчтөнд буцааж хийнэ. Судсаар хийх нь цус сэлбэхтэй төстэй бөгөөд ихэвчлэн 30-90 минут болдог. Энэ нь ихэвчлэн эмнэлгийн нөхцөлд нарийн хяналтан дор хийгддэг.
6. Хяналт ба сэргээх:Судсаар хийлгэсний дараа өвчтөн дор хаяж долоо хоногийн турш ямар нэгэн гаж нөлөөг илрүүлэхийн тулд нарийн хяналтанд байдаг. Зарим нь энэ хугацаанд эмнэлэгт хэвтэж байхад зарим нь амбулаторийн хяналтанд байдаг. Эмчилгээний амжилтыг үнэлэх, аливаа хүндрэлийг арилгахын тулд дараагийн үзлэг, цусны шинжилгээ, сканнерыг хийдэг.

Цагийн тойм:Т-эсийн цуглуулгаас дусаах хүртэл CAR T-эсийн эмчилгээний бүх үйл явц нь ихэвчлэн 3-6 долоо хоног болдог. Биеийн эмчилгээнд үзүүлэх хариу урвалаас хамааран нөхөн сэргээх, хянах хугацаа хэдэн сар үргэлжилж болно.

Энэхүү хувийн эмчилгээ нь таны дархлааны системийг хорт хавдартай тэмцэхэд сургадаг бөгөөд бусад сонголтууд амжилтгүй болсон үед олон хүнд шинэ найдвар төрүүлдэг.

What is the Cost of CAR T-Cell Therapy in India?

The cost of CAR T-cell therapy in India ranges from ₹45,00,000 to ₹70,00,000, which is approximately $52,000 to $85,000. The price is significantly lower than what patients pay in the US or Europe, where similar treatment can exceed $400,000.

This pricing covers much more than just the procedure. In India, most hospitals offer a comprehensive package that includes the entire treatment journey, from your first consultation to your recovery phase. Below is a list of what's typically included in the cost.

• Consultation with Oncology and Transplant Specialists: Covers all pre-treatment discussions and evaluations.
• Leukapheresis Procedure: This process involves collecting T-cells from the patient.
• T-cell Engineering and Manufacturing: This is the most expensive part. It includes modifying the patient's cells in a certified lab using advanced technologies.
• Hospital Admission and ICU Stay (if needed): Includes general ward or ICU expenses during infusion and post-infusion observation.
• Pre-Infusion Chemotherapy: Conditioning therapy to prepare the body for CAR T-cell infusion.
• CAR T-cell Infusion Procedure: Safe administration of the modified cells.
• Post-treatment medications include immunosuppressants, antibiotics, and other drugs to manage side effects.
• Diagnostics and Monitoring: Covers tests like PET scans, CBC, liver/kidney function tests, ECGs, and others throughout the process.
• Follow-up Care for 3–6 Months: Routine check-ups, blood work, and progress tracking after discharge.

The cost may vary slightly depending on your hospital choice, the complexity of your case, and the type of cancer being treated. Still, even the highest range in India remains far more affordable than in the West, making India a preferred destination for this advanced cancer therapy.

Cost Breakdown of CAR T-cell Therapy in India

Knowing the individual components that comprise the total cost of CAR T-cell therapy in India enables patients to plan more effectively. While the complete CAR T-cell treatment package ranges between ₹45,00,000 and ₹70,00,000 ($52,000–$85,000), here's a breakdown of where that money goes:

To begin with, the initial consultation and oncology evaluation costs between ₹10,000 and ₹25,000. It includes a detailed discussion with the cancer specialist, a clinical examination, and the development of a personalized treatment plan.

Next, patients undergo diagnostic tests and imaging, such as PET-CT scans, MRIs, complete blood work, and organ function tests. These are essential to assess disease stage and overall health. This stage usually costs between ₹1,00,000 and ₹2,00,000.

Once cleared for treatment, patients undergo leukapheresis, a process that involves collecting T-cells from the blood. This procedure alone costs around ₹3,00,000 to ₹5,00,000 in most Indian cancer centers.

The most expensive and critical stage is T-cell engineering, where the collected T-cells are modified in a high-tech laboratory to target cancer cells. This step, also known as cell manufacturing, can cost anywhere from ₹25,00,000 to ₹40,00,000 depending on the type of CAR construct used.

Before re-infusing the engineered cells, patients often receive preconditioning chemotherapy. It weakens the existing immune system to make space for the new CAR T-cells. The cost for this preparatory chemotherapy ranges between ₹1,00,000 and ₹2,50,000.

The actual CAR T-cell infusion is done in a hospital setting and may be a short-stay or daycare procedure. The infusion cost is approximately ₹1,50,000 to ₹3,00,000, depending on hospital protocols and the need for special monitoring.

After infusion, patients are typically observed in the hospital for several days to manage side effects and prevent complications. Hospital stay and ICU charges, if needed, add around ₹3,00,000 to ₹6,00,000 to the total cost.

Patients may also require a wide range of medications to manage side effects, such as steroids, antibiotics, painkillers, and immunosuppressants. These supportive medicines cost between ₹2,00,000 and ₹4,00,000 throughout treatment.

Lastly, post-treatment follow-up care (including routine check-ups, lab tests, and response monitoring over the next three to six months) can cost ₹1,00,000 to ₹2,00,000, depending on the frequency of follow-ups and the patient's recovery status.

The transparent cost structure ensures that patients and their families are aware of exactly where their expenses are allocated. In most Indian hospitals, the team also provides pre-approval for international patients to avoid hidden costs.

First Made in India CAR T-Cell Therapy

India made a significant leap in advanced cancer care with the launch of its first homegrown CAR T-cell therapy — NexCAR19. This breakthrough marked an important turning point, making cutting-edge cancer treatment more affordable and accessible to both Indian and international patients.

NexCAR19 was developed through a collaboration between ImmunoACT, a company started at the Indian Institute of Technology (IIT) Bombay, and Tata Memorial Centre, one of India's most trusted cancer institutes. After years of research, clinical trials, and rigorous safety checks, the therapy received regulatory approval in late 2023. It was officially launched in January 2024, offering new hope to patients battling resistant blood cancers.

What makes NexCAR19 special is that it's manufactured within India. In-country manufacturing drastically reduces the cost compared to imported therapies, which used to cost over ₹3–5 crore (more than $400,000). In contrast, NexCAR19 is priced around ₹40,00,000 to ₹50,00,000, making it far more affordable without compromising on quality or safety.

NexCAR19 is currently approved for use in B-cell lymphomas and B-acute lymphoblastic leukemia (B-ALL) that do not respond to standard treatments. It has already shown promising results in early clinical trials, with several patients achieving remission after receiving the therapy.

India's entry into the global CAR T-cell therapy space with NexCAR19 signals a new era of cost-effective, high-tech cancer treatment. Patients from other countries are also starting to consider India as a serious destination for this life-saving option, thanks to the availability of NexCAR19, top-tier oncology centers, and experienced hematologists.

CAR T-cell Therapy Cost Comparison With Different Countries

CAR T-cell therapy is one of the most advanced cancer treatments available, but its cost can vary depending on where it is performed. India is a leading destination for CAR T-cell therapy due to its affordable pricing and world-class medical infrastructure. Here's a comparison of costs across major countries:

As seen above, CAR T-cell therapy in India is nearly 70%–90% more affordable compared to the US, UK, or Germany. Even countries like Singapore and the UAE, which are often considered for medical tourism, have significantly higher prices.

The reduced cost in India does not mean any compromise on quality. Hospitals offering CAR T-cell therapy in India use cutting-edge equipment, advanced immunotherapy labs, and globally trained oncologists. Moreover, with India developing its own CAR T-cell products, such as NexCAR19, the cost is expected to remain within reach for a larger number of patients.

What are the Factors Affecting CAR T-cell Therapy Cost in India?

The cost of CAR T-cell therapy in India can vary from patient to patient. While the average cost ranges between ₹45 lakh and ₹70 lakh, several essential factors can push the price higher or lower. Knowing these cost influencers can help patients and their families plan better.

• Type of Cancer Treated: The cost varies based on the type of cancer, such as B-cell lymphoma, acute lymphoblastic leukemia (ALL), or multiple myeloma. Some cancers need more intensive care and longer treatment cycles.
• Choice of Hospital: Premium hospitals with advanced CAR T-cell labs and ICU facilities may charge more. However, these centers often offer higher success rates and better patient care.
• Type of CAR T-cell Used: India now offers both imported and indigenous options, like NexCAR19. Locally developed therapies are more cost-effective than imported ones.
• Patient's Condition and Stage: Advanced cancer stages may require additional treatment, an ICU stay, or a more extended hospitalization. It can increase the overall cost of CAR T-cell therapy.
• Diagnostic and Pre-Treatment Workup: Before the actual treatment, multiple tests, including PET scans, blood panels, and organ function checks, are necessary. These add to the total cost.
• Hospital Stay and Recovery Time: A longer hospital stay, especially if the patient needs intensive monitoring, will raise the cost. Some may also need post-treatment rehabilitation.
• Post-Treatment Monitoring and Medications: Regular follow-ups, blood tests, and supportive medications are required after infusion. These ongoing costs depend on the patient's response to treatment.
• Support Services for International Patients: Additional services, such as visa assistance, private rooms, translators, and post-discharge support, may incur an extra cost for foreign patients.

Why Choose India for CAR T-cell Therapy?

India is emerging as a trusted global destination for advanced cancer treatments, such as CAR T-cell therapy. With a combination of cutting-edge technology, expert doctors, and affordable prices, India presents a compelling alternative to the expensive treatments available in the US or Europe.

• Affordable CAR T-cell Treatment: India offers CAR T-cell therapy at a much lower cost than the US or Europe, with prices starting from ₹45 lakhs ($52,000), without compromising on quality.
• World-Class Cancer Hospitals: Leading Indian hospitals are equipped with state-of-the-art CAR T-cell labs, ICU facilities, and highly experienced oncology teams.
• Experienced Oncologists and Scientists: Indian doctors and researchers are at the forefront of immunotherapy, offering personalized care and expertise in treating complex cancers.
• Access to Indigenous CAR T-Cell Therapy: India now has its own FDA-approved CAR T-cell treatment, such as NexCAR19, which is both effective and cost-saving for patients.
• Faster Access and Shorter Waiting Times: Unlike in Western countries, patients in India can initiate CAR T-cell therapy promptly, which is particularly crucial for aggressive cancers such as B-cell lymphoma.
• Ideal for International Patients: India's cancer centers offer dedicated services for foreign patients, encompassing everything from airport pickup to post-treatment follow-up care.
• Availability of Clinical Trials: India is actively conducting CAR T-cell therapy trials, providing eligible patients with access to cutting-edge treatments at a reduced cost.

What are the Services Available for International Patients Seeking CAR T-cell Therapy in India?

Traveling abroad for advanced treatment like CAR T-cell therapy can feel overwhelming. To make your journey stress-free, top cancer hospitals in India offer end-to-end support tailored specifically for international patients. The assistance ranges from visa help and airport pickup to translators and post-treatment follow-ups.

• Visa and Travel Assistance: Top hospitals in India offer help with medical visa invitations, quick documentation, and even priority appointments to ease your travel planning.
• Airport Pickup and Local Transport: Hospitals arrange airport pickup, local transport, and even hospital shuttles to ensure a smooth and safe journey from arrival to treatment.
• Affordable Accommodation Options: Partner guesthouses and nearby hotels offer clean and budget-friendly stays for patients and their families, often within walking distance of the hospital.
• Translator and Language Support: Language won't be a barrier. Many hospitals have multilingual staff or arrange interpreters for languages such as Arabic, French, Russian, Spanish, and others.
• Dedicated International Patient Departments: Special teams are assigned to guide international patients through each step, from admission to discharge, ensuring personalized care and comfort.
• Currency Exchange and Payment Support: Hospitals provide on-site foreign exchange services and accept multiple payment methods, including international credit cards, wire transfers, and medical insurance, where applicable.
• Post-Treatment Follow-Up: You'll receive regular updates and online consultations after returning home, ensuring your recovery and monitoring continue uninterrupted.

What is the Success Rate and Treatment Outcomes of CAR T-cell Therapy in India?

CAR T-cell therapy in India has shown highly encouraging results, especially in patients with relapsed or refractory blood cancers. Many hospitals report remission rates of 60% to 80%, depending on the type of cancer and patient condition. For B-cell Acute Lymphoblastic Leukemia (ALL), response rates have been especially promising, even in patients who did not respond to chemotherapy or bone marrow transplants.

What makes these outcomes even more impressive is the rapid access to therapy and strict patient selection protocols, which ensure that only those who are most likely to benefit receive the treatment. With increasing experience, Indian oncologists are continually refining their protocols to enhance both safety and effectiveness.

Clinical results from NexCAR19, India's first domestically developed CAR T-cell product, have also demonstrated a strong safety profile and significant clinical benefits in early trials. Hospitals now follow international treatment protocols, and Indian centers are also part of global clinical research networks, offering patients access to the latest innovations in cancer therapy.

Patients report experiencing quick symptom relief, an improved quality of life, and longer remission periods, especially when treatment is followed by close monitoring and appropriate supportive care.